Chapter 1:

Introduction

In recent years, scientific understanding of depression has expanded beyond the traditional
neurochemical model, ushering in new perspectives that consider the human body as a
complex, interconnected system. Among the most compelling developments is the discovery of
the gut–brain axis, a bidirectional communication network between the gastrointestinal tract
and the central nervous system. This system involves neural, immune, endocrine, and metabolic
pathways, and at the center of it lies the gut microbiome—a diverse community of trillions of
microorganisms residing in the human gastrointestinal tract (Cryan et al., 2019). These
microbes, once thought to merely assist in digestion, are now understood to influence a wide
range of physiological functions, including those that regulate mood, stress, and behavior. Their
influence on brain function has profound implications for psychiatric disorders, particularly
major depressive disorder (MDD).

Major depressive disorder is one of the leading causes of disability worldwide, affecting an
estimated 280 million individuals (World Health Organization, 2023). It presents with a
constellation of emotional, cognitive, and physical symptoms, including persistent sadness,
fatigue, impaired concentration, and changes in appetite and sleep. Despite the widespread use
of antidepressant medications and psychotherapy, approximately one-third of patients
experience treatment resistance or partial response (Rush et al., 2006). These limitations
highlight the urgent need for novel therapeutic targets and a more comprehensive
understanding of depression's underlying mechanisms.

Recent findings suggest that the gut microbiome plays a critical role in shaping the
pathophysiology of MDD. Numerous studies have reported that individuals with depression
often exhibit dysbiosis, or an imbalance in the composition and function of their gut microbiota.
This dysbiosis is typically characterized by reduced microbial diversity and a depletion of
beneficial species such as Faecalibacterium prausnitzii, Coprococcus, and Roseburia—
microorganisms known to produce short-chain fatty acids (SCFAs), particularly butyrate, which
has neuroprotective and anti-inflammatory properties (Nikolova et al., 2021). At the same time,
there is often an overrepresentation of pro-inflammatory bacteria such as Eggerthella,
Clostridium, and members of the Enterobacteriaceae family (Jiang et al., 2015).

These changes in microbial composition can have systemic consequences. SCFAs like butyrate,
propionate, and acetate are not only essential for maintaining gut barrier integrity but also play
a role in modulating inflammation, neuroplasticity, and gene expression in the brain. Butyrate,
in particular, can cross the blood–brain barrier and function as a histone deacetylase inhibitor,
thereby influencing the expression of genes involved in brain-derived neurotrophic factor
(BDNF), a protein vital for neuronal growth and synaptic function (Stilling et al., 2016). Lower
levels of SCFAs have been observed in individuals with MDD, suggesting a possible mechanistic
link between gut microbial metabolites and mood disorders (Zheng et al., 2022).

Dysbiosis may also impair the gut barrier, leading to a condition commonly referred to as “leaky
gut.” This increased intestinal permeability allows bacterial components such as
lipopolysaccharides (LPS) to enter the bloodstream, triggering systemic immune activation.
Elevated levels of pro-inflammatory cytokines, including interleukin-6 (IL-6), tumor necrosis
factor-alpha (TNF-α), and C-reactive protein (CRP), are frequently found in depressed patients
and are associated with symptom severity and treatment resistance (Ng et al., 2022). These
inflammatory signals can reach the brain, where they disrupt neurotransmitter metabolism,
reduce neurogenesis, and impair the functioning of brain circuits involved in mood regulation.

The gut microbiome also interacts with the brain through the vagus nerve, which serves as a
primary communication highway between the gut and the central nervous system. Vagal
afferent fibers detect microbial metabolites and relay this information to the brainstem and
limbic structures, influencing emotional and stress responses. Animal studies have
demonstrated that the beneficial effects of certain probiotics, such as Lactobacillus rhamnosus,
are abolished when the vagus nerve is severed, highlighting its role as a critical conduit in the
microbiota–brain dialogue (Bravo et al., 2011). Furthermore, gut microbes are known to
modulate the hypothalamic–pituitary–adrenal (HPA) axis, the body’s central stress response
system. Germ-free mice display exaggerated HPA responses to stress, which normalize upon
colonization with a healthy microbiota (Sudo et al., 2004). This evidence suggests that the
microbiome contributes not only to baseline emotional regulation but also to resilience under
stress.

Beyond animal models, human research has demonstrated that manipulating the microbiome
can influence mood and cognition. Interventional studies using probiotics—live microorganisms
that confer health benefits—have shown moderate improvements in depressive symptoms,
particularly when used as adjuncts to conventional treatment. For example, clinical trials
involving Lactobacillus helveticus and Bifidobacterium longum have reported reductions in
depression scores, cortisol levels, and systemic inflammation (Messaoudi et al., 2011).
Prebiotics, non-digestible dietary fibers that selectively feed beneficial bacteria, also show
promise. Galacto-oligosaccharides (GOS) and fructo-oligosaccharides (FOS) have been
associated with lower levels of stress hormones and improved emotional processing (Schmidt et
al., 2015). These interventions, often referred to collectively as “psychobiotics,” represent a
growing field within nutritional psychiatry.

Dietary patterns more broadly play a significant role in shaping the gut microbiome and, by
extension, mental health. The Mediterranean diet, rich in fiber, polyphenols, and omega-3 fatty
acids, has been associated with reduced risk of depression and increased abundance of SCFA-
producing bacteria. The SMILES trial, a randomized controlled study, found that adults with
moderate-to-severe depression who adopted a Mediterranean-style diet showed significantly
greater improvements in mood compared to a social support control group (Jacka et al., 2017).
Such findings emphasize the potential of dietary interventions to serve as both preventive and
therapeutic strategies in mental health care.

Despite these advances, several challenges remain in translating microbiome research into
clinical practice. One major limitation is the heterogeneity of existing studies. Differences in
microbial sampling techniques, intervention types, and outcome measures make it difficult to
draw definitive conclusions or establish standardized treatment protocols. Additionally, most
trials have relatively short durations and small sample sizes, limiting their generalizability. The
role of individual variability—such as genetics, age, sex, and environmental exposures—in
shaping the gut–brain axis also warrants further exploration.

Emerging technologies, including metagenomics, metabolomics, and transcriptomics, offer new

avenues for understanding how microbial communities influence host physiology and behavior.
These approaches can identify specific microbial signatures or metabolic pathways associated
with depression, paving the way for personalized treatments. For instance, certain bacteria have
been linked to the synthesis of neuroactive compounds like GABA, serotonin precursors, and
dopamine, all of which are critical in mood regulation (Strandwitz, 2018). As our understanding
deepens, the possibility of developing targeted microbiome-based diagnostics and therapeutics
becomes increasingly realistic.

In addition, fecal microbiota transplantation (FMT)—the transfer of stool from a healthy donor
to a patient to restore microbial balance—has shown potential in preliminary studies for
improving symptoms of depression, particularly in treatment-resistant cases (Kurokawa et al.,
2022). Although still experimental in psychiatric populations, FMT represents an innovative
avenue that underscores the causative role of gut microbes in mental health.

The relevance of the gut microbiome to depression is further supported by its role in early-life
development. The establishment of the microbiota in infancy is influenced by factors such as
mode of delivery, breastfeeding, antibiotic exposure, and maternal stress. These early exposures
can have lasting effects on neurodevelopment, immune function, and vulnerability to
psychiatric disorders later in life (Jašarević et al., 2016). This highlights a potential window of
intervention during the first years of life, where supporting healthy microbial colonization could
have long-term benefits for mental health.

Taken together, the current evidence supports a central role for the gut microbiome in the
onset, progression, and treatment of major depressive disorder. By influencing immune
function, stress physiology, neurotransmitter systems, and brain structure, the microbiota
emerges as a key player in the complex biology of depression. As research continues to unravel
the intricacies of the gut–brain axis, integrating microbiome-based approaches into psychiatric
care holds promise for more personalized, effective, and holistic treatment strategies.
Bravo, J. A., Forsythe, P., Chew, M. V., Escaravage, E., Savignac, H. M., Dinan, T. G., Bienenstock,
J., & Cryan, J. F. (2011). Ingestion of Lactobacillus rhamnosus attenuates stress-induced
corticosterone and alters GABA receptor expression in brain regions associated with anxiety and
depression. Proceedings of the National Academy of Sciences, 108(38), 16050–16055.
[Link]

Cryan, J. F., O’Riordan, K. J., Cowan, C. S. M., Sandhu, K. V., Bastiaanssen, T. F. S., Boehme, M., ...
& Dinan, T. G. (2019). The microbiota–gut–brain axis. Physiological Reviews, 99(4), 1877–2013.
[Link]

Dalile, B., Van Oudenhove, L., Vervliet, B., & Verbeke, K. (2020). The role of short-chain fatty
acids in microbiota–gut–brain communication. Nature Reviews Gastroenterology & Hepatology,
17, 461–478. [Link]

Jašarević, E., Morrison, K. E., & Bale, T. L. (2016). Sex differences in the gut microbiome–brain
axis across the lifespan. Philosophical Transactions of the Royal Society B: Biological Sciences,
371(1688), 20150122. [Link]

Jacka, F. N., O’Neil, A., Opie, R., Itsiopoulos, C., Cotton, S., Mohebbi, M., & Berk, M. (2017). A
randomised controlled trial of dietary improvement for adults with major depression (the
“SMILES” trial). BMC Medicine, 15(1), 23. [Link]

Jiang, H., Ling, Z., Zhang, Y., Mao, H., Ma, Z., Yin, Y., ... & Ruan, B. (2015). Altered fecal
microbiota composition in patients with major depressive disorder. Brain, Behavior, and
Immunity, 48, 186–194. [Link]

Kurokawa, S., Kishimoto, T., Mizuno, S., Masaoka, T., Naganuma, M., Liang, K. C., ... & Mimura,
M. (2022). The effect of fecal microbiota transplantation on psychiatric symptoms in treatment-
resistant depression: A pilot randomized clinical trial. Journal of Affective Disorders, 302, 11–17.
[Link]

Messaoudi, M., Lalonde, R., Violle, N., Javelot, H., Desor, D., Nejdi, A., ... & Cazaubiel, M. (2011).
Assessment of psychotropic-like properties of a probiotic formulation (Lactobacillus helveticus
R0052 and Bifidobacterium longum R0175) in rats and human subjects. British Journal of
Nutrition, 105(5), 755–764. [Link]

Ng, Q. X., Soh, A. Y. S., Loke, W., Lim, D. Y., & Yeo, W. S. (2022). The role of inflammation in
depression: From mechanisms to therapeutic implications. Current Neuropharmacology, 20(3),
338–351. [Link]

Nikolova, V. L., Cleare, A. J., Young, A. H., & Stone, J. M. (2021). Updated review of the gut
microbiota and major depressive disorder: Current status and future directions. Neurobiology of
Stress, 15, 100336. [Link]
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., ... &
Fava, M. (2006). Acute and longer-term outcomes in depressed outpatients requiring one or
several treatment steps: A STAR*D report. American Journal of Psychiatry, 163(11), 1905–1917.
[Link]

Schmidt, K., Cowen, P. J., Harmer, C. J., Tzortzis, G., Errington, S., & Burnet, P. W. J. (2015).
Prebiotic intake reduces the waking cortisol response and alters emotional bias in healthy
volunteers. Psychopharmacology, 232(10), 1793–1801. [Link]
3810-0

Strandwitz, P. (2018). Neurotransmitter modulation by the gut microbiota. Brain Research,

1693, 128–133. [Link]

Stilling, R. M., Dinan, T. G., & Cryan, J. F. (2016). The neuropharmacology of butyrate: The bread
and butter of the microbiota–gut–brain axis? Neurochemistry International, 99, 110–132.
[Link]

Sudo, N., Chida, Y., Aiba, Y., Sonoda, J., Oyama, N., Yu, X. N., ... & Koga, Y. (2004). Postnatal
microbial colonization programs the hypothalamic–pituitary–adrenal system for stress response
in mice. The Journal of Physiology, 558(1), 263–275.
[Link]

World Health Organization. (2023). Depression.

[Link]

Zheng, P., Zeng, B., Liu, M., Chen, J., Pan, J., Han, Y., ... & Xie, P. (2022). The gut microbiome from
patients with major depressive disorder exhibits alterations in gut permeability and
inflammatory markers. Journal of Affective Disorders, 301, 233–240.
[Link]